Arcutis Biotherapeutics wants to eliminate a terrible trade-off for patients with skin conditions. Arcutis stock investors are taking notice.

NEW YORK, March 27, 2025 /PRNewswire/ -- Cardiologists from NYU Langone Heart are showcasing their latest clinical findings ...

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugsRamat Gan, Israel, March 24, 2025 (GLOBE ...

Beyond the surface of your skin, eczema, psoriasis and more can majorly impact your self image and intimate relationships.

Pharmaceutical company Novartis is laying off more than 400 employees at its East Hanover facility as part of a restructuring ...

Steqeyma is indicated for the treatment of plaque psoriasis and psoriatic arthritis in adult and pediatric patients, as well ...

Some evidence suggests a higher risk of liver disease with psoriasis. Certain psoriasis treatments can cause liver toxicity, but the two conditions also share common risk factors, which may ...

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis. Click fo rmy PTGX update.

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a pair of phase 3 trials. The Protagonist Therapeutics-partnered IL-23 ...

“Psoriasis is a chronic condition that increases the risk of ... Given these uncertainties, you should not place undue reliance on any of such forward-looking statements. There can be no guarantee ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing skin and easing symptom severity in patients with plaque psoriasis. Johnson ...

Mice dosed with SFA-002 displayed reduction in psoriasis disease severity and greater reduction in skin thickening compared to etanercept and apremilast in the in vivo model SFA-002 reduced key ...